Tavapadon

To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function

To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function

Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants

Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease

A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

Fixed-Dose Trial in Early Parkinson's Disease (PD)

Flexible-Dose Trial in Early Parkinson's Disease (PD)

Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)

Open-label Trial in Parkinson's Disease (PD)

58-week Open-Label Trial of Tavapadon in Parkinson’s Disease (Tempo-4 Trial)

Expanded Access to Tavapadon